16 January 2020 - Patient preference studies could provide valuable insights to a National Institute for Health and Care Excellence committee into the preferences patients have for different treatment options, especially if the study sample is representative of the broader patient population. 

We identify three main uses of patient preference studies along a technology’s pathway from drug development to clinical use: in early clinical development to guide the selection of appropriate endpoints, to inform benefit risk assessments carried out by regulators and to inform reimbursement decisions made by health technology assessment bodies.

In the context of the National Institute for Health and Care Excellence’s methods and processes, we do not see a role for quantitative patient preference data to be directly incorporated into health economic modelling.

Read Patient-Centered Outcomes Research article